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at the individual level is possible using the unique Central Personal Registry number assigned to each Danish citizen at birth and to residents on immigration.
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Myocardial Infarction
In Denmark, all care for patients with MI, stroke, and other medical emergencies is provided by public hospitals. We used the Danish National Patient Registry (DNPR), covering all Danish hospitals, 19 to identify all Danish-born patients with a first-time inpatient diagnosis of MI during the 30-year period from 1 January 1980 to 31 December 2009. The DNPR contains data on dates of admission and discharge from all Danish nonpsychiatric hospitals since 1977 and from emergency room and outpatient clinic visits since 1995. 19 Each hospital discharge or outpatient visit is recorded in the registry with 1 primary diagnosis and one or more secondary diagnoses classified according to the International Classification of Diseases, Eighth Revision until the end of 1993 and International Classification of Diseases, Tenth Revision thereafter. 19 We identified patients with MI using both primary and secondary diagnoses, excluding patients with a previous or concurrent inpatient or outpatient diagnosis of stroke or transient ischemic attack. Associated International Classification of Diseases codes are provided in Table I in the online-only Data Supplement.
Comparison Cohort
We formed a population-based comparison cohort from the general population using the Danish Central Personal Registry. 20 For each patient with MI, we matched (on sex and age) ≤5 individuals from the general population who were alive on the date the corresponding patient was hospitalized with MI. Each comparison cohort member was assigned an index date corresponding to the admission date for the matched MI patient. We included only members of the general population without a hospital discharge diagnosis of MI, stroke, or transient ischemic attack before or on the index date. If a member of the comparison cohort subsequently experienced an MI, he or she joined the MI cohort at that point.
Comorbidity
We obtained complete information on comorbid conditions before the index date from inpatient and outpatient hospital diagnoses recorded in the DNPR. We identified the following individual comorbidities of prognostic importance: congestive heart failure, stable angina pectoris, atrial fibrillation or flutter, valvular heart disease, intermittent claudication, venous thromboembolism, hypertension, obesity, diabetes mellitus, chronic kidney disease, and chronic pulmonary disease.
Stroke
We obtained information from the DNPR 19 on all inpatient hospitalizations for ischemic stroke, ICH, and SAH after the MI admission/ index date. Approximately one third of all stroke diagnoses in the DNPR has been coded as unspecified stroke. 21 Because more than two thirds of all unspecified strokes are known to be ischemic strokes, 22 we classified unspecified strokes as ischemic strokes. We identified incident strokes using both primary and secondary stroke diagnoses.
Statistical Analysis
We characterized the MI and comparison cohort members according to sex, age group (<60, 60-69, 70-79, or ≥80 years) , and the comorbidities listed in Table 1 . We followed all patients with MI and comparison cohort members from the MI admission/index date until the occurrence of a hospitalization for stroke (ischemic stroke, ICH, or SAH) or until emigration, death, 31 December 2012, or 30 years of follow-up, whichever came first.
Using cumulative incidence functions with death as a competing risk, 23 we illustrated the cumulative stroke risk graphically for both cohorts. Cumulative risks at 30 days, 365 days, and 30 years were computed using the pseudovalue approach. 24 For the 1 to 30 days, 31 to 365 days, and 1 to 30 years of follow-up periods, we computed the stroke rate and used stratified Cox proportional-hazards regression (ie, retaining matching by age and sex in the analysis) to compute unadjusted and adjusted hazard ratios as a measure of the stroke rate ratios (SRRs) between the MI and the comparison cohorts. In the regression model, we adjusted for the individual comorbidities listed in Table 1 . For all estimates, we computed 95% confidence intervals (CIs). The proportional-hazards assumption was assessed graphically using log-log plots. Because the assumption was violated within the whole period, we examined SRRs separately within 1 to 30 days, 31 to 365 days, and 1 to 30 years of follow-up periods.
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To assess temporal changes in stroke risk during the study period, we stratified the regression analyses by the calendar periods listed in Table 1 . In these analyses, a 1 to 5 years instead of a 1 to 30 years of follow-up period was used for long-term risk assessment, to allow for sufficient follow-up time in the last calendar period (2005) (2006) (2007) (2008) (2009) ). In addition, we stratified the analyses by sex, age, and the individual comorbidities listed in Table 1 to detect whether cardiovascular diseases had any major influence on stroke risk. In all stratified analyses, we dissolved the matching and adjusted instead for the matching factors (age and sex) and the individual comorbidities.
In sensitivity analyses, we repeated the analyses separating ischemic stroke into specified ischemic stroke and unspecified stroke and extended the hypertension and diabetes mellitus definitions to also include medication, which was available in the last study period (2005) (2006) (2007) (2008) (2009) . For the temporal trends in stroke risk, we also computed the cumulative risks for each calendar period in addition to SRRs.
Because this study did not involve contact with patients or any intervention, approval from the Danish Scientific Ethical Committee and patient consent were not required. The study was approved by the Danish Data Protection Agency (record number 1-16-02-1-08).
Results
A total of 258 806 patients with first-time MI were identified during the study period. The comparison cohort consisted of 1 244 773 sex-and age-matched persons from the general population without a previous MI. Comorbidities were more common among patients with MI than among comparison cohort members (Table 1) .
Ischemic Stroke
Cumulative risk functions for the MI and comparison cohorts during the 30-year follow-up period are presented in Figure 1 and corresponding cumulative risks after 1 to 30 days, 31 to 365 days, and 1 to 30 years are presented in Table 2 . After 30 years of follow-up, the cumulative risk of ischemic stroke was 12.6% for the MI cohort and 11.9% for the comparison cohort. During 1 to 30 days of follow-up, the adjusted SRR was 31.9 (95% CI, 28.4-35.8), comparing the MI cohort with the matched general population comparison cohort. The adjusted SRR remained elevated during both the 31 to 365 days (3.1; 95% CI, 3.0-3.3) and 1 to 30 years of period (1.6; 95% CI, 1.6-1.6).
ICH and SAH
After 30 years of follow-up, the cumulative risk of ICH was lower in the MI cohort (1.2%) than in the comparison cohort (1.6%) because of competing mortality in the MI cohort. The adjusted SRR was elevated during the first 1 to 30 days (21.8; 95% CI, ) and 31 to 365 days (2.1; 95% CI, 1.9-2.5) and declined to near unity during the ensuing 1 to 30 years (1.1; 95% CI, 1.0-1.2).
The cumulative risk of SAH after 30 years of follow-up was low for both the MI (0.24%) and comparison cohort (0.29%). During the first 30 days of follow-up, the adjusted SRR was 16.6 (95% CI, . The adjusted SRR remained elevated during 31 to 365 days (1.5; 95% CI, 1.1-2.1) after which there was no difference in risk between the MI and the comparison cohorts (SRR, 1.1; 95% CI, 0.94-1.2).
Temporal Trends in Stroke Risk
Changes in adjusted SRR during the 30-year study period are presented in Figure 2 . For ischemic stroke, an abrupt decrease was observed for all 3 periods of follow-up during the first half of the study period. Thereafter, the adjusted SRR decreased only little.
For ICH, there was a modest drop in the 1-to 30-day adjusted SRR during the first half of the study period, after which it increased to ≈30 during 1995 to 1999 and settled at ≈12 during 2005 to 2009. During 31 to 365 days and 1 to 5 years of follow-up periods, a decline was observed in the first decade of the study period, after which the SRR increased marginally.
For SAH, a bimodal pattern was observed during the 1 to 30 days and 31 to 365 days of follow-up, with the SRR declining during the first 2 decades of the study period, followed by an abrupt increase in the last decade. During 1 to 5 years of follow-up, the SRRs remained close to unity throughout the study period apart from a peak during 1985 to 1989.
Additional Analyses
In stratified analyses by sex and age, the adjusted SRR was slightly higher among females and younger age groups during the first 1 to 30 days and 31 to 365 days of follow-up. However, for SAH the adjusted SRR was higher for males than for females. No effect modification by sex or age was observed for the remaining 1 to 30 years of follow-up (Table  II in the online-only Data Supplement).
Stratified analyses by individual comorbidities are presented in Table III in the online-only Data Supplement. In these analyses, adjusted SRRs were slightly higher for strata with no comorbidity. This was expected because of the lower absolute risk of stroke.
In the sensitivity analyses, results were unchanged when separating ischemic stroke into specified ischemic stroke and unspecified stroke (Table IV in the online-only Data Supplement). When including medication in the definition of hypertension and diabetes mellitus during 2005 to 2009, the prevalence of these diseases in the MI cohort increased from 20.6% to 35.7% for hypertension and from 9.7% to 12.7% for diabetes mellitus (Table V in the onlineonly Data Supplement). However, the SRRs were consistent with the primary results (Table VI in the online-only Data Supplement). Cumulative risks by calendar periods were continuously higher in the MI cohort compared with the comparison cohort (Table VII in the online-only Data Supplement).
Discussion
MI was a strong risk factor for all stroke types during 1 to 30 days and 31 to 365 days of follow-up. During 1 to 30 years of follow-up, the risk remained elevated for ischemic stroke, but leveled out for ICH and SAH. Throughout the 30-year study period and for all 3 follow-up periods, a continuous decrease in stroke risk was observed for ischemic stroke, whereas risks of ICH and SAH decreased only during the first 2 decades after which a marginal increase was observed for SAH. The observed pattern of ischemic versus hemorrhagic stroke risk after MI may reflect secondary MI prevention strategies. 26 During the last study decade, guidelines recommended an aggressive antithrombotic regimen with dual antiplatelet therapy (DAPT) for 1 year after 
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MI (ie, aspirin plus an ADP receptor inhibitor) followed by lifelong aspirin treatment. 26 This may explain, in part, why the risk of hemorrhagic stroke was elevated only during the first year after MI. Similarly, the introduction of DAPT in the beginning of the last study decade may explain why the initial decline in ICH and SAH risks was followed by a marginal increase toward the end of the study period.
27,28 The notable decrease in ischemic stroke risk between 1985 to 1989 and 1990 to 1994 coincides with the broad implementation of aspirin treatment for patients with MI in the early Mechanisms underlying elevated risk of ischemic stroke for up to 30 years after MI likely include shared risk factors for atherosclerosis, which account for the mutual pathophysiological disarray underlying ischemic stroke and MI. 30 The extent to which MI itself is responsible for increased risk of ischemic stroke remains unclear. Cardioembolic stroke has been reported to account for 60% of in-hospital post-MI ischemic strokes.
13 As only about one fifth of all ischemic strokes is cardioembolic, 31 the high proportion of cardioembolic strokes among post-MI ischemic strokes may be because of complications of MI, such as atrial fibrillation or regional wall motion abnormality with formation of left ventricular thrombi. However, 3 large trials have shown no association between anticoagulation therapy in patients with MI and stroke occurrence, suggesting a minor role of cardioembolic stroke. [32] [33] [34] Our findings merit increased awareness of both ischemic and hemorrhagic stroke during the first year after MI and attention to ischemic stroke thereafter. Prevention of Antithrombotic therapy after MI follows current guidelines recommending 1 year of DAPT followed by lifelong aspirin therapy. 28 A recent trial found that continuation of the DAPT regimen beyond 1 year after MI 35 reduced 3-year stroke risk without a concomitant increase in serious bleeding events, including intracranial hemorrhage. Prolongation of DAPT after MI is intriguing in light of our finding that only the risk of ischemic stroke was increased beyond 1 year after MI. However, we cannot rule out that the increased risk of hemorrhagic stroke during the first year could be related to DAPT treatment itself, as supported by the increased 1-to 30-day and 31-to 365-day SRR for SAH during the 2000 to 2009 period where DAPT was implemented.
Several study strengths and limitations should be considered. We had sufficient sample size and follow-up time to examine short-and long-term risk of stroke after MI. The population-based design within a uniformly organized healthcare system limited the risk of selection biases because of inclusion of specific hospitals, health insurance systems, or age groups.
17 Follow-up was complete for all patients. 18 The positive predictive values of inpatient diagnoses in the DNPR have previously been validated and found to be 97% for ischemic stroke, 74% for ICH, 67% for SAH, 22 and >90% for MI.
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Because we classified unspecified strokes as ischemic strokes, a few ICHs (≈6%) were almost certainly misclassified as ischemic strokes. 22 However, separate analyses of specified ischemic stroke and unspecified stroke did not change our main results. Although we adjusted for the most important potential confounders (eg, hypertension, obesity, diabetes mellitus, and chronic pulmonary disease as an indirect measure of smoking) 37, 38 and in sensitivity analyses ruled out residual confounding by hypertension and diabetes mellitus, we cannot rule out unknown or unmeasured confounders (eg, physical activity and comedication).
In conclusion, we found that the risks of ischemic stroke, ICH, and SAH were increased in the first year after MI. During the ensuing 1 to 30 years of follow-up, the risk remained elevated for ischemic stroke, whereas the risks receded for ICH and SAH. We observed a declining trend in the risk of post-MI stroke. This was most pronounced during the first half of the study period, particularly for ischemic stroke. The increased risk of ischemic stroke beyond 1 year after MI merits continued clinical attention to this frequently disabling or fatal complication. 
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Figure 2. Short-and long-term temporal trends in the adjusted stroke rate ratio after myocardial infarction during 1980 to 2009, with 95% confidence intervals (CIs). All estimates were adjusted for congestive heart failure, angina pectoris, atrial fibrillation or flutter, heart valve disease, intermittent arterial claudication, venous thromboembolism, hypertension, obesity, diabetes mellitus, chronic kidney disease, and chronic pulmonary disease. a For long-term risk assessment, a 1 to 5 year instead of a 1-to 30-year follow-up period was used, to allow for follow-up during the last calendar period (ie, 2005-2009 18.8 (5.9-59.6) 2.5 (1.2-4.9) 1.0 (0.62-1.7) *Adjusted for congestive heart failure, angina pectoris, atrial fibrillation or flutter, heart valve disease, intermittent arterial claudication, venous thromboembolism, hypertension, obesity, diabetes, chronic kidney disease, and chronic pulmonary disease. Abbreviations: ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage. 9 (0.6-1.4) 0.9 (0.5-1.4) 0.9 (0.5-1.4) †Rates per 1000 person-years. ‡Adjusted for congestive heart failure, angina pectoris, atrial fibrillation or flutter, heart valve disease, intermittent arterial claudication, venous thromboembolism, hypertension, obesity, diabetes, chronic kidney disease, and chronic pulmonary disease. §Adjusted for congestive heart failure, angina pectoris, atrial fibrillation or flutter, heart valve disease, intermittent arterial claudication, venous thromboembolism, hypertension (defined by either a previous diagnosis of hypertension or a claimed prescription for a glucose lowering drug within 180 days prior to myocardial infarction), obesity, diabetes (defined by either a previous diagnosis of diabetes or combination treatment of at least two redeemed prescriptions for different of antihypertensive drugs within 180 days prior to myocardial infarction), chronic kidney disease, and chronic pulmonary disease. Abbreviations: CI, confidence interval; MI, myocardial infarction; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage. 
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